Literature DB >> 22854685

Predictors of cure, amputation and follow-up dropout among patients with mycetoma seen at the Mycetoma Research Centre, University of Khartoum, Sudan.

Hagir A M Zein1, Ahmed H Fahal, El Shiekh Mahgoub, Tasnam A El Hassan, Manar E Abdel-Rahman.   

Abstract

Complete cure of mycetoma is difficult to achieve and recurrence is common. The study objective was to determine the predictors of cure, amputation and follow-up dropout among the studied individuals with mycetoma. This prospective study included 1544 patients with confirmed mycetoma, of whom 1242 had eumycetoma and 302 actinomycetoma. They were treated and followed up regularly. Data were collected and analysed using logistic regression models to determine the predictors. In the eumycetoma group, longer treatment duration (OR=1.9; 95% CI 1.2-3.1) and absence of history of disease recurrence (OR=24.2; 95% CI 7.7-76.3) were significant predictors of increased odds of cure from mycetoma. A lesion size of 5-10 cm (OR=0.5; 95% CI 0.3-0.8) or >10 cm (OR=0.7; 95% CI 0.4-1.0) and combined medical treatment and surgery (OR=0.004; 95% CI 0.001-0.011) were each significant predictors of reduced odds of cure. Follow-up dropout among this group was high (54%). Large lesions (5-10 cm, OR=0.5, 95% CI 0.4-0.7; >10 cm, OR=0.6; 95% CI 0.5-0.9), amputations (OR=0.3; 95% CI 0.1-0.6) and longer treatment duration (OR=0.5; 95% CI 0.4-0.7) were significant predictors of reduced odds of follow-up dropout. In the actinomycetoma group, medical treatment was the only significant predictor of cure. Follow-up dropout among this group was also high (55.6%). Long treatment duration was a significant predictor of reduced odds of dropout (OR=0.5; 95% CI 0.3-0.8). There is a great demand for effective and efficient mycetoma treatment. Counselling and health education of patients is badly needed to encourage early reporting and treatment to reduce mycetoma's medical, social and economic impacts.
Copyright © 2012 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22854685     DOI: 10.1016/j.trstmh.2012.07.003

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  31 in total

1.  An unusual cause of an ankle mass.

Authors:  Aditya Prinja; Catherine Roberts; Tom Doherty; Michael J Oddy
Journal:  BMJ Case Rep       Date:  2014-09-26

2.  Detection of (1→3)-β-d-Glucan in Eumycetoma Patients.

Authors:  Ahmed H Fahal; Malcolm A Finkelman; Yonglong Zhang; Wendy W J van de Sande
Journal:  J Clin Microbiol       Date:  2016-07-20       Impact factor: 5.948

3.  In vitro susceptibility testing for black grain eumycetoma causative agents.

Authors:  Wendy W J van de Sande
Journal:  Trans R Soc Trop Med Hyg       Date:  2021-04-14       Impact factor: 2.184

4.  The synthetic synergistic cinnamon oil CIN-102 is active against Madurella mycetomatis, the most common causative agent of mycetoma.

Authors:  Mickey Konings; Kimberly Eadie; Wilson Lim; Ahmed H Fahal; Johan Mouton; Nicolas Tesse; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2021-06-09

5.  Mycetoma herbal treatment: the Mycetoma Research Centre, Sudan experience.

Authors:  Eshraga A Ezaldeen; Ahmed Hassan Fahal; Anjom Osman
Journal:  PLoS Negl Trop Dis       Date:  2013-08-22

Review 6.  The mycetoma knowledge gap: identification of research priorities.

Authors:  Wendy W J van de Sande; El Sheikh Maghoub; Ahmed H Fahal; Michael Goodfellow; Oliverio Welsh; Ed Zijlstra
Journal:  PLoS Negl Trop Dis       Date:  2014-03-27

7.  Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella.

Authors:  Wilson Lim; Mickey Konings; Florianne Parel; Kimberly Eadie; Nikolaos Strepis; Ahmed Fahal; Annelies Verbon; Wendy W J van de Sande
Journal:  Med Mycol       Date:  2022-02-02       Impact factor: 3.747

8.  Madurella mycetomatis is highly susceptible to ravuconazole.

Authors:  Sarah Abdalla Ahmed; Wendy Kloezen; Frederick Duncanson; Ed E Zijlstra; G Sybren de Hoog; Ahmed H Fahal; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2014-06-19

9.  The combination of amoxicillin-clavulanic acid and ketoconazole in the treatment of Madurella mycetomatis eumycetoma and Staphylococcus aureus co-infection.

Authors:  Najwa A Mhmoud; Ahmed Hassan Fahal; El Sheikh Mahgoub; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2014-06-19

10.  The in vitro antifungal activity of sudanese medicinal plants against Madurella mycetomatis, the eumycetoma major causative agent.

Authors:  Hassabelrasoul Elfadil; Ahmed Fahal; Wendy Kloezen; Elhadi M Ahmed; Wendy van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2015-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.